VEGF Gene Test (Vascular Endothelial Growth Factor, Angiogenesis & Cardiovascular Health)

• Identify whether you carry VEGF variants, such as +405 C/G (rs2010963) and promoter polymorphisms, that have been associated with differences in VEGF levels and cardiovascular risk in some populations.
• Help explain a tendency toward microvascular vulnerability or resilience, including patterns in wound healing, peripheral circulation, or retinal and kidney microvascular changes, when interpreted in the right context.
• Inform how aggressively to manage classic cardiovascular risk factors and support vascular health through lifestyle, nutrition, and targeted interventions.
• Provide context for responses to hypoxia, ischemia, and high‑demand states, such as intensive training, altitude exposure, or tissue repair after injury or surgery.
• Clarify your angiogenesis and vascular maintenance profile alongside blood pressure, lipids, inflammatory markers, and imaging, so long‑term heart, brain, eye, and kidney strategies can be grounded in your biology.

VEGF (often referring specifically to VEGF‑A) encodes vascular endothelial growth factor A, a key signalling protein that regulates blood vessel formation, growth, and permeability. VEGF‑A belongs to a family of VEGF proteins that signal through specific tyrosine kinase receptors on endothelial cells, primarily VEGFR‑1 and VEGFR‑2.

VEGF expression is tightly controlled by oxygen levels, growth factors, and cytokines. Hypoxia, mechanical stress, and inflammation increase VEGF production, which then drives angiogenesis, vascular remodelling, and changes in vascular permeability. Genetic variation in the VEGF gene influences how strongly VEGF responds to these signals and how much is produced at baseline.

VEGF sits at the centre of the body's angiogenesis machinery. When tissues experience low oxygen, injury, or increased metabolic demand, VEGF is upregulated and secreted. It binds to VEGF receptors on endothelial cells, triggering intracellular signalling cascades that promote endothelial cell survival, proliferation, migration, and tube formation. This leads to new capillary growth and remodelling of existing vessels.

VEGF also increases vascular permeability and influences endothelial junctions, allowing plasma proteins and cells to exit the circulation during healing and inflammation. Beyond blood vessels, VEGF has roles in lymphangiogenesis, neurovascular development, neuroprotection, and maintenance of fenestrated capillaries in specialized tissues such as the kidney, liver, and endocrine organs.

VEGF contributes to three interconnected systems: physiological angiogenesis and tissue repair, pathological angiogenesis and vascular disease, and long‑term cardiovascular and microvascular health. On the positive side, VEGF is essential for normal development, wound healing, exercise‑induced capillary growth in muscle, and collateral vessel formation during ischemia.

On the negative side, excessive or dysregulated VEGF signalling drives pathological angiogenesis in cancer, proliferative retinopathies, and certain inflammatory diseases, and influences plaque neovascularisation in atherosclerosis. Specific VEGF polymorphisms, including +405 C/G and other promoter variants, have been associated in research with altered risk of coronary artery disease, myocardial infarction, and cardiovascular mortality in some populations, likely through effects on endothelial integrity, lipid interactions, and vessel wall biology.

It is easy to assume that VEGF genotyping, circulating VEGF levels, and vascular imaging tell the same story, but they address different layers. VEGF genotyping shows inherited variants that influence how strongly the gene is expressed in response to stimuli and at baseline. These variants remain constant and provide a trait‑level view of angiogenic responsiveness.

VEGF blood levels reflect current signalling activity under your present conditions, such as hypoxia, inflammation, cancer, chronic disease, or treatment with anti‑VEGF agents. Vascular imaging and functional tests (retinal scans, coronary imaging, ankle‑brachial index, microvascular flow) show the anatomical and functional consequences in your vessels. A person with a VEGF genotype associated with higher expression may still have healthy vessels if lifestyle and other factors are favourable, while someone with neutral genotypes may develop vascular disease through unmanaged risk factors. Combined information is most useful.

The influence of VEGF variants is shaped by cardiovascular risk factors, lifestyle, and disease states far more than by the gene alone. Several modifiable factors can either buffer any genetic disadvantages or amplify them.

• Blood pressure and vascular load: Hypertension increases shear stress and damages the endothelium, driving compensatory and pathological angiogenesis. In the presence of VEGF variants associated with altered signalling, this can tilt risk toward atherosclerosis and microvascular damage.
• Lipids and metabolic health: Dyslipidaemia, insulin resistance, and central adiposity promote endothelial dysfunction and plaque formation. VEGF‑related differences can interact with these to influence plaque neovascularisation and stability.
• Smoking, pollution, and inflammation: Smoking and chronic exposure to air pollution increase oxidative stress and endothelial injury and can enhance or disrupt VEGF responses, pushing the system toward pathological angiogenesis.
• Physical activity and conditioning: Regular aerobic training supports healthy capillary density, endothelial function, and nitric oxide signalling. This can help balance VEGF‑mediated angiogenesis toward protective rather than pathological patterns.
• Chronic diseases and treatments: Cancer, diabetes, chronic kidney disease, and autoimmune conditions all alter VEGF signalling. Anti‑VEGF therapies and other drugs further modify how VEGF pathways behave in clinical settings.
• Nutrient status and microvascular support: Adequate omega‑3 fats, B vitamins, antioxidants, and other micronutrients support endothelial integrity and vascular repair, helping to buffer VEGF‑related vulnerabilities.

Yes. Many people with VEGF polymorphisms never experience specific symptoms attributable solely to these variants. VEGF acts within a large network of angiogenic and inflammatory signals, and its genetic variants tend to modify risk curves and responses rather than causing discrete syndromes on their own.

Differences often appear only when combined with other risk factors, disease states, or environmental stressors. For example, a variant associated with slightly higher cardiovascular risk may become clinically relevant only in someone with poorly controlled blood pressure, smoking, and dyslipidaemia, and may be largely neutral in a person with a very healthy lifestyle and good risk‑factor control.

VEGF genotypes mainly differ in promoter and regulatory variants within the VEGFA gene that affect transcription, along with some polymorphisms in coding and untranslated regions. Several have been studied in relation to cardiovascular, ocular, cancer, and inflammatory diseases.

• +405 C/G (rs2010963) polymorphism: This widely studied variant in the 5′ UTR has been linked in some cohorts to higher risk of coronary artery disease and cardiovascular mortality, likely through effects on VEGF expression and endothelial integrity. Certain genotypes may modestly increase risk of myocardial infarction or heart failure after infarction.
• Promoter variants such as −2578 C/A and rs699947: Changes in the promoter can influence VEGF transcription and have been associated in some studies with risk of myocardial infarction and coronary artery disease, often in interaction with other risk factors.
• Other VEGFA polymorphisms (for example rs3025039 and related variants): Additional variants have been associated with susceptibility to cardiovascular disease, diabetic complications, and some cancers, often through altered VEGF levels and vascular responses.
• Haplotype patterns: Combinations of multiple VEGF SNPs form haplotypes that may more accurately reflect VEGF expression capacity than single variants, particularly when considering specific diseases or populations.

For DNA‑based VEGF testing, preparation is simple because your genotype is fixed and not affected by current disease activity, diet, or medications. The main step is clarifying how you intend to use the results, such as refining cardiovascular risk assessment, framing microvascular or ocular concerns, or informing long‑term prevention strategies.

Cheek swab, saliva, or blood‑based VEGF genotyping does not require fasting. If you are also undergoing lipid panels, glucose tests, inflammatory markers, or imaging on the same day, follow the preparation instructions for those assessments, which may include fasting or avoiding intense exercise just before testing.

A VEGF test is most useful when the result will change how you structure cardiovascular and microvascular prevention plans, or how you interpret risk in the context of other findings, rather than as a stand‑alone curiosity. It is best viewed as one piece within a broader risk and resilience picture.

• Cardiovascular risk with family history: In people with strong family history of coronary artery disease or stroke, VEGF genotyping can add nuance on top of classic risk factors and may support more assertive prevention.
• Microvascular and endothelial concerns: For individuals with early microvascular complications (for example in the retina or kidneys) relative to their other risk factors, VEGF and other vascular genes can provide helpful context.
• Performance and recovery planning: For those using high‑volume training, altitude exposure, or repeated tissue stress, VEGF sits alongside other vascular and mitochondrial markers in tuning training, recovery, and risk management.
• Comprehensive prevention and longevity strategies: When building broad DNA and blood testing programmes, VEGF helps anchor the angiogenesis and vascular repair dimension of your long‑term plan.